DiaMedica Therapeutics Inc.DMACNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
45.36%
↑ 36% above average
Average (9y)
33.32%
Historical baseline
Range
High:99.01%
Low:-76.13%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | 45.36% |
| 2023 | 67.24% |
| 2022 | -10.56% |
| 2021 | 6.83% |
| 2020 | 3.86% |
| 2019 | 74.70% |
| 2018 | 41.05% |
| 2017 | 81.81% |
| 2016 | 99.01% |
| 2015 | -76.13% |